Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation
Frontiers in Pharmacology · 18.08.2026 · 17
DOI: 10.3389/fphar.2026.1941847 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.08.2026. Verfasst von Fenglei Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
- Drug Metabolism, Gilead Sciences Inc., Foster City, CA, United States.
- Model-Informed Drug Development, Bayer Healthcare SAS, Lille, France.
- US Food and Drug Administration, Silver Spring, MD, United States.
Zitieren
APA
Huang, F., Lai, Y., Dallmann, A., & Yang, X. (2026). Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1941847
Vancouver
Huang F, Lai Y, Dallmann A, Yang X. Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1941847
BibTeX
@article{Huang2026,
author = {Huang, Fenglei and Lai, Yurong and Dallmann, André and Yang, Xinning},
title = {Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1941847}
}
EUVIMED